Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Open-label Extension Study To Assess The Safety And Efficacy Of Certolizumab Pegol As Additional Medication To Methotrexate In Chinese Subjects With Active Rheumatoid Arthritis Who Participated In RA0044.

NCT02319642 is registered in ClinicalTrials.gov with UCB Pharma SA as lead sponsor.

NCT NCT02319642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02319642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Open-label Extension Study To Assess The Safety And Efficacy Of Certolizumab Pegol As Additional Medication To Methotrexate In Chinese Subjects With Active Rheumatoid Arthritis Who Participated In RA0044.
Lead sponsor
UCB Pharma SA
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2014
Completion date
December 31, 2016
Enrollment
347 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis